LA JOLLA, Calif., Nov. 29 /PRNewswire-FirstCall/ -- Stephen Ferrone, CEO of Immunosyn Corporation , will make presentations about the company to institutional investors, independent brokerages, dealers, investment banking firms and related capital market service providers at the National Investment Banking Association (NIBA) conference at the Luxor Hotel in Las Vegas, NV on Thursday, November 29 and Friday, November 30, 2007.
“It is important that we increase market awareness of Immunosyn Corporation, our vision and the steps which have been taken, moving us closer to achieving our goals,” says Stephen D. Ferrone, CEO and President of Immunosyn. “We are therefore privileged to present our company to the elite group of broker/dealers, investment bankers and institutional investors at the NIBA conference.”
Immunosyn’s company objectives, overview and product information will be communicated to target audiences at select conferences such as NIBA. Presentations will be made which include market data, research information and milestones achieved. As part of Immunosyn’s presentation at NIBA, Mr. Ferrone will focus on the biopharmaceutical SF-1019, including information about regulatory approvals and results of a recent study.
A video version of the Immunosyn presentation that is being shared with institutional investors at the NIBA Conference will be launched on the company’s News / Media page at http://www.immunosyn.com on Friday, November 30, 2007, 9:00 AM EST.
About the National Investment Banking Association
The National Investment Banking Association is a national trade association of regional and independent brokerages, investment banking firms, and related capital market service providers. NIBA member firms have successfully completed some 850+ equity offerings totaling approximately $9.5 billion in new capital for America’s finest emerging growth companies.
About Immunosyn Corporation
La Jolla, CA-headquartered Immunosyn Corporation (IMYN.OTC.BB) plans to market and distribute life enhancing therapeutics. Currently, the company has exclusive worldwide rights from its largest shareholder, Argyll Biotechnologies, LLC, to market, sell and distribute SF-1019, a compound that was developed from extensive research into Biological Response Modifiers (BRMs). Argyll Biotechnologies, LLC has initiated the process for regulatory approval of SF-1019 in several countries and preparations for clinical trials are underway in both the US and Europe. Research suggests that SF-1019 has the potential to affect a number of clinical conditions including complications from Diabetic Mellitus such as Diabetic Neuropathy (DN) and diabetic ulcers (DU), auto-immune disorders such as Multiple Sclerosis (MS) and neurological disorders such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS). (For more information on Immunosyn and SF-1019 go to http://www.immunosyn.com)
The above news release contains forward-looking statements. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and are subject to a wide range of business risks, external factors and uncertainties. Actual results may differ materially from those indicated by such forward-looking statements. For additional information, please consult the Company’s most recent public filings and Annual Report on Form 10-K for its most recent fiscal year. The Company assumes no obligation to update the information contained in this press release, whether as a result of new information, future events or otherwise.
CONTACT: Bill Kraus, or Lisa Baker, or Devon Blaine, all of The Blaine
Group, +1-310-360-1499, fax, +1-310-360-1498, blaine@blainegroupinc.com,
all for Immunosyn Corporation
Web site: http://www.immunosyn.com/
